Legal Proceedings (Details) - Pending Litigation $ in Millions |
Feb. 28, 2023
USD ($)
|
Jan. 23, 2023
USD ($)
|
Dec. 20, 2019
patent
|
---|---|---|---|
Curia Demand for Arbitration | |||
Loss Contingencies [Line Items] | |||
Damages sought | $ 76.7 | ||
Curia's Claims in Arbitration | |||
Loss Contingencies [Line Items] | |||
Damages sought | $ 4.2 | ||
Par Pharmaceutical, Inc. et al. v. Eagle Pharmaceuticals, Inc. (Vasopressin) | |||
Loss Contingencies [Line Items] | |||
Number of patents, claims dismissed | patent | 3 |
X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Definition The value (monetary amount) of the award the plaintiff seeks in the legal matter. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
X | ||||||||||
- Definition Number of another entity's patents that the entity was found not to have infringed. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|